Apogee Therapeutics recently completed a follow-on equity offering of approximately US$403,000,000, issuing 5,750,000 common shares at US$70.00 each after reporting positive 52-week Phase 2 APEX data ...
CrowdStrike's top-line growth remains impressive, but a demanding valuation leaves the stock vulnerable to emerging artificial intelligence risks.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results